Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Unknown 7Completed 6Recruiting 5Terminated 2Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 6

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Genitourinary 6

Conditions

Breast Neoplasms 4349Neoplasms 3050Prostatic Neoplasms 1902Colorectal Neoplasms 1736Lung Neoplasms 1551Carcinoma, Non-Small-Cell Lung 1268Pancreatic Neoplasms 981Leukemia, Myeloid, Acute 950Multiple Myeloma 946Lymphoma 911Head and Neck Neoplasms 893Leukemia 851Precursor Cell Lymphoblastic Leukemia-Lymphoma 830Neoplasm Metastasis 792Colonic Neoplasms 783Carcinoma, Hepatocellular 761Ovarian Neoplasms 756Melanoma 752Stomach Neoplasms 739Rectal Neoplasms 700Brain Neoplasms 694Lymphoma, Non-Hodgkin 658Leukemia, Lymphocytic, Chronic, B-Cell 617Uterine Cervical Neoplasms 605Lymphoma, Follicular 559Glioblastoma 538Recurrence 537Hodgkin Disease 530Esophageal Neoplasms 527Myelodysplastic Syndromes 507

Interventions

enzalutamide 3Abiraterone Acetate 2abiraterone 1Prednisone 1Flutamide 1Crizotinib 1Control Groups 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × OTHER × Castration-resistant Prostate Cancer × Clear all
NCT02025010 2025-04-15

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
60 enrolled 17 charts
Genitourinary

Castration-resistant Prostate Cancer

NCT05549778 2023-07-11

PEACe

Jiangnan University

Phase 1/2 Completed
12 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT03247010 2022-11-09

Bone Marrow Suppression and Recovery During Radionuclide Treatment

Rigshospitalet, Denmark

Completed
68 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT02207504 2022-01-06

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
24 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT02346578 2021-09-16

Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

Osaka City University

Phase 2 Completed
104 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT02429193 2020-01-13

BARRIER-P

University Health Network, Toronto

Phase 2 Completed
16 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡